Author’s response to reviews

Title: Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation

Authors:

Li-Fen Han (13655083639@163.com)
Jian-Ming Zheng (zhengjianming@fudan.edu.cn)
Li-qing Zheng (wom70@163.com)
Hai-bing Gao (gaohb605@163.com)
Li-xia Chen (532918102@qq.com)
Qing-ling Xu (491098648@qq.com)
Yi-hong Chai (caiyihong1966@126.com)
Xin Zhang (67431566@qq.com)
Chen Pan (panchencry@163.com)
Lv-Feng Yao (yaolf05@163.com)

Version: 4 Date: 23 Jun 2019

Author’s response to reviews:

INFD-D-18-00581R3

Telbivudine reduces mother-to-child transmission in chronic hepatitis B patients

Li-Fen Han; Jian-Ming Zheng; Li-qing Zheng; Hai-bing Gao; Li-xia Chen; Qing-ling Xu; Yi-hong Chai; Xin Zhang; Chen Pan; Lv-Feng Yao

BMC Infectious Diseases

Dear BMC Infectious Diseases Editors and Reviewers:
Thank you for your letter and for the reviewers’ comments concerning our manuscript entitled “Telbivudine reduces mother-to-child transmission in chronic hepatitis B patients” (ID: INFD-D-18-00581R3). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. The main corrections in the paper and the responds to the reviewer’s comments are as flowing.

Responds to the reviewer’s comments:

1. Please rename “Introduction” to “Background”.
   Response: we rename “Introduction” to “Background” according to reviewer’s comment.

2. In the section 'Ethics Approval and Consent to Participate', please state whether the informed consent obtained was written or verbal. If verbal, please state the reason and whether the ethics committee approved this procedure.
   Response: The informed consent obtained was written. That the informed consent obtained was verbal is not forbidden in our hospital. (line#110)

3. We note that you have not included an acknowledgements section in the declarations. If you have no acknowledgements please put ‘Not Applicable’ in this section.
   Response: we rewrite an acknowledgements section in the declarations according to reviewer’s comment. (line#315)

4. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions.
   Response: we rewrite the paper according to reviewer’s comment. Thank you very much. We wish change our article title “Telbivudine reduces mother-to-child transmission in chronic hepatitis B patients” as “Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation”.

We tried our best to improve the manuscript and made some changes in the manuscript. These changes will not influence the content and framework of the paper. We appreciate for Editors/Reviewers’ warm work earnestly, and hope that the correction will meet with approval.
Once again, thank you very much for your comments and suggestions.

We would like to express our great appreciation to you and reviewers for comments on our paper. Looking forward to hearing from you.

Thank you and best regards.

Yours sincerely,

Corresponding author:
Lv-feng Yao
Email: yaolf05@163.com